全文获取类型
收费全文 | 1728篇 |
免费 | 186篇 |
国内免费 | 49篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 110篇 |
妇产科学 | 28篇 |
基础医学 | 163篇 |
口腔科学 | 69篇 |
临床医学 | 152篇 |
内科学 | 445篇 |
皮肤病学 | 32篇 |
神经病学 | 29篇 |
特种医学 | 209篇 |
外科学 | 263篇 |
综合类 | 99篇 |
预防医学 | 95篇 |
眼科学 | 10篇 |
药学 | 99篇 |
中国医学 | 3篇 |
肿瘤学 | 148篇 |
出版年
2023年 | 15篇 |
2022年 | 9篇 |
2021年 | 35篇 |
2020年 | 28篇 |
2019年 | 14篇 |
2018年 | 33篇 |
2017年 | 51篇 |
2016年 | 50篇 |
2015年 | 35篇 |
2014年 | 73篇 |
2013年 | 80篇 |
2012年 | 46篇 |
2011年 | 40篇 |
2010年 | 80篇 |
2009年 | 78篇 |
2008年 | 50篇 |
2007年 | 86篇 |
2006年 | 52篇 |
2005年 | 54篇 |
2004年 | 54篇 |
2003年 | 31篇 |
2002年 | 41篇 |
2001年 | 46篇 |
2000年 | 39篇 |
1999年 | 35篇 |
1998年 | 83篇 |
1997年 | 75篇 |
1996年 | 78篇 |
1995年 | 57篇 |
1994年 | 52篇 |
1993年 | 50篇 |
1992年 | 26篇 |
1991年 | 20篇 |
1990年 | 38篇 |
1989年 | 34篇 |
1988年 | 36篇 |
1987年 | 24篇 |
1986年 | 36篇 |
1985年 | 28篇 |
1984年 | 14篇 |
1983年 | 19篇 |
1982年 | 12篇 |
1981年 | 8篇 |
1980年 | 10篇 |
1979年 | 10篇 |
1978年 | 12篇 |
1977年 | 7篇 |
1976年 | 18篇 |
1975年 | 14篇 |
1965年 | 9篇 |
排序方式: 共有1963条查询结果,搜索用时 15 毫秒
1.
By injecting small amounts of CO2 through a needle, one can move bowel or bladder from the intended path of instruments during interventional procedures. The technique worked well in six of seven cases in the pelvis and retroperitoneum; it was not effective in the mediastinum or midabdomen (n = 6). 相似文献
2.
The use of pelvic ultrasonography in the evaluation of adolescents with pelvic inflammatory disease 总被引:2,自引:0,他引:2
N Golden H Cohen G Gennari S Neuhoff 《American journal of diseases of children (1960)》1987,141(11):1235-1238
To evaluate the use of pelvic ultrasonography in the diagnosis and management of female adolescents with pelvic inflammatory disease (PID), sonograms of 60 patients with PID were compared with those of 40 age-matched controls. Sonograms were evaluated for adnexal volume, adnexal adherence, uterine size, and the presence of cul-de-sac fluid. Eleven (19.3%) of the 57 patients with PID, in whom adequate sonograms were obtained, had tubo-ovarian abscesses; in seven of these patients, the abscesses were diagnosed ultrasonographically before suspected clinically. Even in those patients without tubo-ovarian abscesses, the mean (+/- SD) adnexal volume in the PID group was significantly larger than that of the control group (11.0 +/- 6.8 cm3 vs 5.2 +/- 2.7 cm,3 respectively). Adnexal adherence, uterine size, and the presence of cul-de-sac fluid were not useful in differentiating patients with PID from normal controls. Pelvic ultrasonography can be a useful adjunct in the diagnosis and management of PID in adolescents and may, in some instances, provide diagnoses in the absence of clinical findings. 相似文献
3.
Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal,bone-active drug ipriflavone 总被引:2,自引:0,他引:2
Hormone replacement therapy is the optimal therapeutic choice for postmenopausal syndrome. While low doses of estrogens (0.3 mg/day of conjugated estrogens) can counteract neurovegetative menopausal symptoms, higher doses (0.625 mg/day of conjugated estrogens) are required to prevent bone loss in postmenopausal women. Experimental and clinical studies have shown that ipriflavone, a non-hormonal isoflavone derivative, is effective in the prevention and treatment of postmenopausal osteoporosis. The aim of the present investigation was to evaluate the efficacy and toler-ability of ipriflavone and very low doses of equine conjugated estrogens on bone loss in early postmenopausal women. Eighty-three healthy postmenopausal women (50.3±0.7 years) were enrolled for this 1-year multicenter study. All subjects were randomly allocated to receive: double placebo (n=24; group A), placebo plus conjugated equine estrogens 0.30 mg/day (n=31; group B) or conjugated equine estrogens 0.30 mg/day plus oral ipriflavone 200 mg tris in die at meals (n=28; group C), according to a double-masked design. Among women who completed the treatment period (valid completers), those of group A showed a progressive decrease in forearm bone density (FBD; measured by dual photon absorptiometry) that reached 1.7% after 12 months. The women in group B maintained their FBD in the first 6 months of treatment but, at the end of the study, showed a bone loss of 1.4% compared with basal values. By contrast, women in group C showed a significant increase in FBD after 1 year of treatment (+5.6%;p<0.01). Bothvalid completers andintention to treat analyses revealed a significant difference (p<0.05) between group A and group C over the study period. None of the treatments produced significant changes of biochemical markers of bone turnover, while hot flushes and other climacteric symptoms were significantly reduced after the sixth month of treatment in women receiving estrogens. Adverse events were generally mild, and did not differ among the groups. The results of this study suggest that low doses of estrogens combined with ipriflavone could represent a new therapeutic approach to the treatment of the postmenopausal syndrome. 相似文献
4.
外科医生和手术室人员经常接触手术设备产生的烟气,病人也会暴露于烟气中,特别是腹腔镜手术中产生的烟气滞留于腹腔内这一密闭空间并被吸收.这些烟气是一种与香烟烟气相似的毒性物质,然而对这种毒性物质的影响还未引起足够重视.应该采取必要措施尽可能减少手术中烟气的不良影响. 相似文献
5.
6.
7.
8.
D. Agnusdei G. Crepaldi G. Isaia G. Mazzuoli S. Ortolani M. Passeri L. Bufalino C. Gennari 《Calcified tissue international》1997,61(2):142-147
One hundred ninety-eight postmenopausal women (aged 50–65 years) with vertebral bone density (VBD) 1 SD below the mean value
for normal, age-matched, postmenopausal subjects were enrolled in six Italian centers and 134 completed 2 years of treatment.
All subjects were randomly allocated to a 2-year treatment with oral ipriflavone (200 mg t.i.d.) or a matching placebo, according
to a double-blind, parallel group design. All patients also received an oral daily calcium supplement of 1 g as calcium carbonate.
VBD and markers of bone turnover were measured at baseline, and every 6 months. A complete routine analysis of liver and kidney
functions along with hematological parameters were measured before and at the end of treatment period. The valid completers
analysis showed a significant increase of VBD in ipriflavone-treated women with average percent changes of +1.4 after 1 year,
and +1% at the end of treatment period (P < 0.05). The placebo group presented a significant decrease of VBD after 2 years of treatment (P < 0.05). The difference between treatments was significant (P < 0.01). The intention to treat analysis confirmed the significant decrease of VBD in the placebo group, with no changes
in ipriflavone-treated women. Skeletal ALP significantly decreased in ipriflavone-treated women (P < 0.05). Serum BGP and urine HOP/Cr showed a significant decrease only in ipriflavone-treated women, suggesting an inhibitory
effect on bone turnover rate. Adverse reactions, mainly gastrointestinal, occurred to a similar extent in the two treatment
groups. The evaluation of patients' compliance, assessed by residual tablets count, revealed a drug intake of more than 80%
after 2 years in 92.5% and 92.8% of patients treated with ipriflavone or placebo, respectively. This study demonstrates that
ipriflavone can prevent bone loss in postmenopausal women with low bone mass.
Received: 1 April 1996 / Accepted: 5 March 1997 相似文献
9.
10.